Pharmacology, Toxicology and Pharmaceutical Science
Rituximab
72%
Diffuse Large B Cell Lymphoma
67%
Chemotherapy
57%
Remission
48%
Survival Rate
47%
Overall Survival
47%
Progression Free Survival
44%
Acute Myeloid Leukemia
37%
Etoposide
32%
Nonhodgkin Lymphoma
30%
Large Cell Lymphoma
27%
Doxorubicin
25%
Vincristine
25%
Cyclophosphamide
23%
Disease
22%
Bleomycin
22%
Peripheral T Cell Lymphoma
22%
Prednisolone
21%
Disease Free Survival
18%
Nucleoside Diphosphate Kinase A
16%
Clinical Trial
16%
B Cell Lymphoma
15%
Acute Leukemia
13%
Granulocyte Colony Stimulating Factor
13%
Neutropenia
11%
Anaplastic Large Cell Lymphoma
11%
Thrombocytopenia
10%
Transient Ischemic Attack
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Herpes Zoster
9%
Retrospective Study
8%
Chemotherapy Regimens
7%
Combination Therapy
7%
Mantle Cell Lymphoma
7%
Lactate Dehydrogenase
7%
Chromosome Aberration
7%
Ifosfamide
6%
Vasculotropin
6%
Hemopoietic Growth Factor
6%
Hodgkin Disease
6%
Classical Hodgkin Lymphoma
6%
Nucleolysin TIA 1 Isoform P40
6%
Methotrexate
6%
Hematologic Malignancy
6%
Imatinib
6%
Myelodysplastic Syndrome
6%
Neoplasm
6%
Leukemia
6%
Circulating Tumor DNA
6%
Cyclophosphamide Plus Doxorubicin Plus Etoposide Plus Prednisolone Plus Rituximab Plus Vincristine
6%
Medicine and Dentistry
Diffuse Large B-Cell Lymphoma
100%
Rituximab
66%
Progression Free Survival
37%
Acute Myeloid Leukemia
34%
Overall Survival
32%
B Cell
32%
B-Cell Lymphoma
28%
Large-Cell Lymphoma
27%
Survival Rate
26%
Prognostic Factor
22%
Elderly Patient
18%
Germinal Center
17%
Disease
16%
Mantle Cell Lymphoma
15%
Immunophenotyping
15%
Arm
15%
Retrospective Study
15%
Non-Hodgkin Lymphoma
14%
Methotrexate
13%
Induction Chemotherapy
13%
Thyroid Gland
13%
Immunoglobulin Light Chain
13%
Heavy Chain
13%
Human Herpesvirus 8
13%
Drug Megadose
13%
Peripheral T-Cell Lymphoma
13%
Disease Free Survival
13%
Doxorubicin
13%
Vincristine
13%
Cyclophosphamide
13%
Immunoglobulin
10%
Prednisolone
10%
CD20
10%
Karyotype
10%
Clinical Trial
9%
Cyclophosphamide Plus Doxorubicin Plus Prednisolone Plus Rituximab Plus Vincristine
9%
Lymphocyte
9%
Disseminated Herpes Zoster
9%
Hematology
9%
Central Nervous System
8%
Angioimmunoblastic T-Cell Lymphoma
8%
Allogenic Bone Marrow Transplantation
8%
Autologous Tumor Cell
8%
Nucleoside Diphosphate Kinase A
8%
Myelodysplastic Syndrome
8%
Multivariate Analysis
8%
Cyclin D1
8%
Clinical Significance
7%
Epstein Barr Virus
7%
Mantle Cell Lymphoma International Prognostic Index
7%
Keyphrases
Diffuse Large B-cell Lymphoma (DLBCL)
28%
Acute Myeloid Leukemia
20%
Intravascular Large B-cell Lymphoma (IVLBCL)
20%
Lymphoma Patients
17%
Chemotherapy
15%
Japan Clinical Oncology Group
13%
Retrospective Analysis
13%
Rituximab-containing Chemotherapy
13%
B-cell Lymphoma
13%
Treatment Outcome
13%
CD5 Positive
13%
Aggressive non-Hodgkin Lymphoma
13%
Nm23
13%
Progression-free Survival
12%
Clinical Outcomes
11%
Rituximab
10%
Unselected Patients
10%
Aggressive Lymphoma
10%
Immunophenotyping
9%
CD10
9%
Lymphoma
9%
Overall Survival
9%
Confidence Interval
9%
Japan
9%
Induction Chemotherapy
9%
Treatment Results
9%
Complete Remission
9%
Non-Hodgkin Lymphoma
8%
Induction Therapy
8%
Myelodysplastic Syndrome
8%
Poor Prognosis
8%
Secondary Leukemia
8%
Extranodal
8%
Disease-free Survival
7%
Leukemia Cells
7%
Consecutive Patients
7%
Prognostic Impact
7%
Central Nervous System Recurrence
7%
Adult Acute Lymphoblastic Leukemia
6%
BEACOPP
6%
Flow Cytometric
6%
NUP98-HOXA9
6%
Intensive Care Medicine
6%
MYC Translocation
6%
Large Granular Lymphocyte
6%
Proliferative Effect
6%
MHC Class I Antigen
6%
Chromosome Rearrangement
6%
Diagnostic Specimen
6%
Circulating Tumor DNA (ctDNA)
6%